Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.

Literature DB >> 9132317

A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.

D Biasi, P Caramaschi, A Carletto, S Zeminian, F Schiavon, L M Bambara.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1997 PMID： 9132317 DOI： 10.1007/bf02238778

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

Keyword Cloud
References

× No keyword cloud information.

18 in total

1. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.

Authors: M V Kyle; G Belcher; B L Hazleman
Journal: J Rheumatol Date: 1992-09 Impact factor: 4.666

2. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

Authors: N J McHugh; M Csuka; H Watson; G Belcher; A Amadi; E F Ring; C M Black; P J Maddison
Journal: Ann Rheum Dis Date: 1988-01 Impact factor: 19.103

3. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study.

Authors: J N Fiessinger; M Schäfer
Journal: Lancet Date: 1990-03-10 Impact factor: 79.321

4. Use of computerized digital thermometry for diagnosis of Raynaud's phenomenon.

Authors: P Caramaschi; O Codella; G Poli; L Perbellini; D Biasi; L M Bambara; R Corrocher; G De Sandre
Journal: Angiology Date: 1989-10 Impact factor: 3.619

5. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors: F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal: Ann Intern Med Date: 1994-02-01 Impact factor: 25.391

10. Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size.

Authors: E F Smith; W Gallenkämper; R Beckmann; T Thomsen; G Mannesmann; K Schrör
Journal: Cardiovasc Res Date: 1984-03 Impact factor: 10.787

A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.

1. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.

2. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

3. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study.

4. Use of computerized digital thermometry for diagnosis of Raynaud's phenomenon.

5. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

6. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease.

7. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Review 8. Measuring disease activity and severity in scleroderma.

9. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.

10. Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size.